PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China https://t.co/EnYxRpijpr https://t.co/Hge8AR9t72
114 followers
906 followers
New article: PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China https://t.co/3F5Vc5gUKg #lungcancer #oncology https://t.co/Og4OHfW6SC
6,534 followers
New research: PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China: Objective Our previous economic assessment found that nivolumab was not cost-effective for Chinese… https://t.co/